Samsung Bioepis, Teva expand biosimilar pact to target US and Europe

Samsung Bioepis and Teva Pharmaceutical Industries have entered into an agreement on commercializing the former’s up to six potential biosimilar ca...

TD Cowen inició la cobertura sobre Teva Pharmaceutical Industries en una nota de investigación el jueves. Establecieron una calificación de "compra" y un precio objetivo de 55,00 dólares para la empresa.

Teva Pharmaceutical Industries (TEVA) has an average rating of buy and mean price target of $44.59,

TEL AVIV, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) - TAPI (Technology API Services) today announced the appointment of Serge Rogasik as its Chief Executive Officer. Mr. Rogasik will lead a global business that combines a broad API portfolio, deep scientific and technical capabilities, and an extensive global operations network serving customers worldwide. “I am honored to join TAPI at such an important moment in its evolution," said Mr. Rogasik. "TAPI combines a unique set of capabilities, assets and talented people with a well-earned reputation as a trusted partner to customers worldwide. As the pharmaceutical industry increasingly focuses on supply chain resilience and geographic diversification, TAPI is uniquely positioned to support its customers. Few companies can match one of the industry's broadest technology platforms and an integrated manufacturing and RD network spanning India, the Middle East, Europe and the Americas. I am excited by the momentum in the business

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Obtenga informe gratuito) obtuvo una recomendación consensuada de "Compra moderada" de las doce firmas de calificación que actualmente cubren la empresa, informa MarketBeat. Un analista de investigación de acciones calificó la acción con una calificación de mantener y once la calificaron con una calificación de mantener.

Built on substance, not hype, Teva's mega rally is just getting started.

Built on substance, not hype, Teva's mega rally is just getting started.